UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~March 101, 2020

FORTY SEVEN, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-38554	47-4065674
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
1490 O’Brien Drive, Suite A Menlo Park, California		94025
(Address of Principal Executive Offices)		(Zip Code)

1490 O’Brien Drive, Suite A Menlo Park, California		94025
(Address of Principal Executive Offices)		(Zip Code)

(650) 352-4150

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~Trading Symbol~~TradingSymbol(s)		Name of each ~~exchange~~exchangeon on which registered
Common Stock, $0.0001 par value		FTSV		The Nasdaq ~~Stock~~Global ~~Market~~Select ~~LLC~~Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 1.01 Entry into a Material Definitive Agreement.

On ~~January~~March 101, 2020, Forty Seven, Inc., ~~entered into~~ a ~~Controlled~~Delaware ~~Equity OfferingSM Sales~~corporation ~~Agreement~~ (the “~~Sales~~Company” ~~Agreement~~or “Forty Seven”), ~~with~~entered ~~Cantor~~into ~~Fitzgerald &~~an ~~Co.,~~Agreement asand ~~our~~Plan ~~sales~~of ~~agent~~Merger (the “~~Sales~~Merger ~~Agent~~Agreement”), ~~pursuant~~by ~~to which we may offer~~ and ~~sell~~among ~~from~~the ~~time to time~~Company, ~~after~~Gilead ~~March 10~~Sciences, ~~2020~~Inc., ~~through~~a ~~the~~Delaware ~~Sales~~corporation ~~Agent shares of our common stock, par value $0.0001 per share~~ (“~~Common Stock~~Parent”), ~~having an aggregate offering price of up to~~or ~~$100,000,000 (the~~ “~~Shares~~Gilead”), inand ~~such~~Toro ~~amounts~~Merger asSub, ~~we may specify by notice to the Sales Agent~~Inc., ina ~~accordance~~Delaware ~~with~~corporation ~~the terms~~ and ~~conditions~~a ~~set~~wholly-owned ~~forth~~subsidiary inof ~~the~~Parent ~~Sales Agreement~~(“Purchaser”).

~~Sales,~~Pursuant ifto ~~any~~the Merger Agreement, ofand upon the ~~Shares~~terms ~~pursuant~~and subject to the ~~Sales~~conditions ~~Agreement~~thereof, ~~may~~Parent behas ~~made~~agreed into ~~negotiated~~cause ~~transactions~~Purchaser orto ~~transactions~~commence ~~that~~a tender ~~are~~offer ~~deemed~~(the ~~to be~~ “~~at-the-market~~Offer” ~~offerings~~) asto ~~defined~~purchase inall ~~Rule~~of ~~415 under~~ the ~~Securities~~outstanding ~~Act,~~shares ~~including~~of ~~sales~~common ~~made~~stock ~~directly~~of on the ~~Nasdaq~~Company ~~Global~~(the ~~Select Market~~“Shares”), orpar ~~sales made~~value to$0.0001 orper ~~through~~share, ~~a market maker~~ other than onany anShares ~~exchange.~~held ~~Under~~immediately prior to the effective ~~Sales~~time ~~Agreement,~~of wethe ~~will~~Merger ~~set~~(as ~~the~~defined ~~parameters~~below) ~~for~~by the ~~sale~~Company of(or ~~shares,~~held ~~including~~in the ~~number~~Company’s oftreasury) ~~shares~~and toany beShares ~~issued,~~held ~~the~~immediately ~~time~~prior ~~period~~to ~~during~~the ~~which~~effective ~~sales~~time ~~are~~of ~~requested~~the toMerger beby ~~made~~Parent, ~~limitation~~ onPurchaser ~~the~~or ~~number~~any ofother ~~shares~~direct ~~that~~or ~~may~~indirect bewholly ~~sold~~owned subsidiary inof ~~any~~Parent, ~~one~~at ~~trading~~a ~~day~~price ~~and~~of ~~any~~$95.50 ~~minimum~~per ~~price~~Share ~~below~~(the ~~which~~“Offer ~~sales~~Price”), ~~may~~net ~~not~~to bethe ~~made.~~seller Wein ~~are~~cash, ~~not~~without ~~obligated~~interest toand ~~sell~~subject to any ~~Shares~~required ~~under~~withholding ~~the~~of ~~Sales Agreement~~taxes.

The ~~Shares~~Offer will beinitially ~~offered~~remain ~~and~~open ~~sold~~for ~~pursuant~~20 tobusiness ~~our~~days ~~shelf~~from ~~registration~~the ~~statement~~date ~~on Form S-3 (File No~~of commencement of the Offer. ~~333-235877)~~ ~~which~~If ~~was~~at ~~automatically~~the ~~effective~~scheduled ~~upon~~expiration ~~filing~~time ~~with~~of the Offer any of the ~~Securities~~conditions ~~and~~to ~~Exchange~~the ~~Commission~~Offer onhave ~~January 10,~~not ~~2020.~~been Wesatisfied ~~filed~~(unless asuch ~~prospectus~~condition ~~supplement, dated~~is ~~January 10,~~waivable ~~2020,~~by ~~with~~Purchaser ~~the~~or ~~Securities~~Parent and ~~Exchange~~has ~~Commission~~been inwaived), ~~connection~~Parent ~~with~~will cause Purchaser to, extend the ~~offer~~Offer ~~and~~to ~~sale~~permit the satisfaction of ~~the~~all ~~Shares.~~Offer conditions.

The ~~offering~~ obligation of ~~shares~~Purchaser ofto ~~our~~accept ~~common~~for ~~stock~~payment, and pay for, Shares validly tendered (and not validly withdrawn) pursuant to the ~~Sales~~Offer is ~~Agreement~~subject ~~will~~to ~~terminate~~satisfaction or waiver, to the extent permitted under applicable legal requirements, of customary conditions, including (i) there being validly tendered and not validly withdrawn Shares that, considered together with all other Shares (if any) beneficially owned by Parent and its affiliates, represent one more Share than 50% of the sum of (x) the total number of Shares outstanding at the expiration of the Offer, plus (y) the total number of Shares the Company would be required to issue upon conversion, settlement, exchange or exercise of all options, warrants, rights or securities vested and outstanding at the expiration of the Offer that are convertible, exchangeable or exercisable into Shares (whether then outstanding or for which the conversion, settlement, exchange or exercise date has already occurred, but in any event without duplication), (ii) the expiration or termination of the ~~Sales~~waiting ~~Agreement~~period as(or ~~permitted~~any ~~therein.~~extension Wethereof) ~~and~~applicable to the Offer ~~Sales~~under ~~Agent~~the ~~may~~Hart-Scott-Rodino ~~each~~Antitrust ~~terminate~~Improvements Act of 1976, as amended (the ~~Sales~~“HSR ~~Agreement~~Act”), at(iii) the absence of any ~~time~~law ~~upon~~or ~~ten~~order ~~days~~in any jurisdiction in which Parent or the Company has material business operations prohibiting the consummation of the Offer or the Merger, (iv) the accuracy of the Company’s representations and warranties (subject to customary materiality qualifiers), (v) the Company’s compliance or performance in all material respects of its obligations, covenants and agreements it is required to comply with or perform at or prior ~~notice~~to the expiration of the Offer, and (vi) the absence, since the date of the Merger Agreement, of any change, circumstance, condition, development, effect, event, occurrence or state of facts which, individually or in the aggregate, has had, or would reasonably be expected to have, a Material Adverse Effect (as defined in the Merger Agreement) that is continuing.

~~The~~Following ~~Sales~~the ~~Agreement~~consummation ~~contains~~of ~~customary~~the ~~representations,~~Offer ~~warranties~~ and ~~agreements~~subject byto ~~us,~~the ~~and~~terms ~~indemnification rights~~ and ~~obligations~~ conditions of the ~~parties.~~Merger ~~The Sales~~ Agreement, ~~provides~~Purchaser ~~that the Sales Agent~~ will be ~~entitled~~merged towith ~~compensation~~and into ~~for~~the ~~its~~Company ~~services~~(the of“Merger”) uppursuant to ~~3.0%~~Section 251(h) of the ~~gross~~General ~~sales~~Corporation ~~price~~Law ~~per~~of ~~share~~the State of ~~all~~Delaware ~~shares~~(the ~~sold~~“DGCL”), ~~through~~with the ~~Sales~~Company ~~Agent~~continuing ~~under~~as the ~~Sales~~surviving ~~Agreement.~~corporation in the ~~Under~~Merger. At the ~~terms~~effective time of the ~~Sales~~Merger, ~~Agreement~~each Share, weincluding ~~have~~any ~~agreed~~Shares subject to ~~indemnify~~vesting ~~the~~or ~~Sales~~employment ~~Agent~~based ~~against~~forfeiture ~~certain~~conditions ~~specified~~(“Restricted ~~types~~Shares”) of(other ~~liabilities,~~than ~~including~~(i) Shares ~~liabilities~~held ~~under~~by the ~~Securities~~Company ~~Act~~(or ofheld ~~1933,~~in asthe Company’s ~~amended~~treasury), to(ii) ~~contribute~~Shares toheld ~~payments~~by ~~the~~Parent, ~~Sales~~Purchaser, ~~Agent~~or ~~may~~any ~~be required~~other todirect ~~make~~or inindirect ~~respect~~wholly ofowned ~~these~~subsidiary ~~liabilities,~~of Parent and to(iii) Shares ~~reimburse~~held ~~the~~by ~~Sales~~stockholders ~~Agent~~who ~~for~~have ~~certain~~properly ~~expenses.~~exercised Inand ~~the~~perfected ~~ordinary~~their ~~course~~demands for appraisal of such ~~business,~~Shares in accordance with the ~~Sales~~DGCL ~~Agent~~and orhave ~~their~~neither ~~respective~~withdrawn ~~affiliates~~nor ~~from~~lost ~~time~~such rights prior to the effective time ~~have~~of ~~provided~~the ~~and~~Merger) ~~may~~will inbe ~~the~~converted ~~future~~into ~~provide various~~the ~~investment~~right ~~banking,~~to ~~commercial~~receive ~~banking~~an ~~and~~amount ~~financial~~in ~~advisory~~cash ~~services~~equal to the ~~company~~Offer ~~and/or~~Price, ~~its~~without ~~affiliates~~interest, ~~for~~without regard to any vesting or employment based forfeiture conditions which ~~they~~were ~~have~~applicable ~~received~~to orthe ~~may~~corresponding ~~receive~~Restricted ~~customary~~Shares, ~~compensation~~and subject to any required withholding of taxes.

WeThe ~~intend~~Merger toAgreement ~~use~~includes ~~the~~customary ~~net proceeds from the sale~~representations, ifwarranties ~~any, of the securities offered in the offering to conduct our clinical trials, to fund continued research~~ and ~~development~~covenants of ~~magrolimab~~the ~~in several applications~~Company, toParent ~~fund other research~~ and ~~development activities, and for working capital and other general corporate purposes~~Purchaser. We may also use a portion of the net proceeds to acquire or invest in companies, medicines, intellectual property or technologies that are complementary to our own, although we have no current commitments or agreements with respect to any acquisitions or investments.

The ~~above~~Company ~~summary~~has ofagreed to customary “no-shop” restrictions on its ability to solicit alternative acquisition proposals from third parties and engage in discussions or negotiations with third parties regarding alternative acquisition proposals. Notwithstanding these restrictions, the ~~Sales~~Company ~~Agreement~~may ~~does~~under ~~not~~certain ~~purport~~circumstances provide, pursuant to bean ~~complete~~acceptable confidentiality agreement, information (including non-public information) to and isengage ~~qualified~~in or otherwise participate in ~~its~~discussions ~~entirety~~or bynegotiations ~~reference~~with third parties with respect to a bona fide written alternative acquisition proposal that the ~~Sales~~board ~~Agreement~~of directors of the Company has determined in good faith, after consultation with its financial advisor and outside legal counsel, constitutes or would reasonably be expected to aresult ~~copy~~in ~~which~~a isSuperior ~~attached~~Offer (as ~~Exhibit~~defined ~~1.1~~in the Merger Agreement) and that failure to ~~this~~take ~~Current~~such ~~Report~~action onwould ~~Form 8-K and~~be ~~incorporated~~inconsistent ~~herein~~with bythe ~~reference~~board’s fiduciary duties under applicable legal requirements. The ~~legal~~Merger ~~opinion~~Agreement also requires that the Company’s board of ~~Cooley~~directors ~~LLP~~recommend ~~relating~~that tothe stockholders of the Company accept the Offer and tender their Shares ~~being~~to ~~offered~~Purchaser pursuant to the ~~Sales~~ ~~Agreement~~Offer isand ~~filed~~not, asamong ~~Exhibit~~other things, (i) ~~5.1~~withdraw or withhold (or modify or qualify in a manner adverse to ~~this~~Parent ~~Current~~or ~~Report on Form 8-K.~~Purchaser), or publicly propose to withdraw or withhold (or modify or qualify in a

~~Item~~ manner adverse to Parent or Purchaser), the Company’s board of director recommendation, (ii) adopt, approve, recommend or declare advisable, or publicly propose to adopt, approve, recommend or declare advisable, any alternative acquisition proposal, (iii) fail to publicly affirm its recommendation within three business days following Parent’s written request after the announcement of an alternative acquisition proposal (subject to certain limitations related to serial requests and during any matching rights period), (iv) fail to publicly reaffirm the Company’s board of director recommendation and recommend that the Company’s stockholders reject any competing third-party tender or exchange offer within ten days after commencement or (v) fail to include the recommendation in the Company’s Tender Offer Solicitation/Recommendation Statement on Schedule 14D-9 when filed with the U.01S. ~~Financial~~Securities ~~Statements~~and Exchange Commission (the “SEC”) or disseminated to the Company’s stockholders. Notwithstanding these restrictions, the board of directors of the Company is permitted, subject to the terms and ~~Exhibits~~conditions set forth in the Merger Agreement, to change its recommendation and terminate the Merger Agreement to accept a Superior Offer or change its recommendation in response to an Intervening Event (as defined in the Merger Agreement), subject in each case to certain matching rights in favor of Parent.

The Merger Agreement contains certain termination rights for both the Company and Parent, including if (di) the ~~Exhibits~~closing has not occurred prior to June 1, 2020, but subject to an automatic 90-day extension if the condition related to the expiration or termination of the waiting period under the HSR Act has not been satisfied or waived, (ii) if consummation of the Offer or the Merger is legally prohibited or enjoined or (iii) if there has been a breach by the other party that is not cured such that, in the case of the Company, the applicable Offer conditions would not be satisfied or, in the case of Parent, the consummation of the Offer or the Merger would be prevented. The Merger Agreement may also be terminated (i) by the Company, subject to the terms and conditions set forth in the Merger Agreement, to accept a Superior Offer and (ii) by Parent if the board of directors of the Company has effected a Company Adverse Change Recommendation (as defined in the Merger Agreement). Upon termination of the Merger Agreement (i) by the Company to accept a Superior Offer or (ii) by Parent following a Company Adverse Change Recommendation, the Company will be required to pay Parent a termination fee of $160 million. Under certain additional circumstances described in the Merger Agreement, the Company must also pay Parent such termination fee if the Merger Agreement is terminated and, within 12 months following such termination, the Company recommends or enters into certain alternative acquisition arrangements and such acquisition is subsequently consummated.

Exhibit		Description
1.1		Sales Agreement, by and between Forty Seven, Inc. and Cantor Fitzgerald & Co., dated January 10, 2020.
5.1		Opinion of Cooley LLP.
23.1		Consent of Cooley LLP (contained in Exhibit 5.1).

The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which is filed as Exhibit 2.1 hereto and which is incorporated herein by reference. The Merger Agreement has been filed to provide information to investors regarding its terms. It is not intended to provide any other factual information about the Company, Parent or Purchaser, their respective businesses, or the actual conduct of their respective businesses during the period prior to the consummation of the Offer, the Merger or the other transactions contemplated by the Merger Agreement. The Merger Agreement and this summary should not be relied upon as disclosure about the Company or Parent. None of the Company’s stockholders or any other third parties should rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or conditions of the Company, Parent, Purchaser or any of their respective subsidiaries or affiliates. The Merger Agreement contains representations and warranties that are the product of negotiations among the parties thereto and that the parties made to, and solely for the benefit of, each other as of specified dates. The assertions embodied in those representations and warranties are subject to qualifications and limitations agreed to by the respective parties and are also qualified in important part by confidential disclosure schedules delivered in connection with the Merger Agreement. The representations and warranties may have been made for the purpose of allocating contractual risk between the parties to the agreements instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors.

~~SIGNATURES~~Item 8.01 Other Events.

~~Pursuant~~On toMarch 2, 2020, the ~~requirements~~Company ofand ~~the~~Parent ~~Securities~~issued ~~Exchange~~a ~~Act~~joint ofpress ~~1934,~~release announcing the ~~Registrant~~Merger ~~has~~Agreement, ~~duly~~a ~~caused~~copy ~~this~~of ~~report~~which tois befiled ~~signed~~as onExhibit 99.1 ~~its~~and ~~behalf~~incorporated herein by ~~the undersigned hereunto duly authorized~~reference.

Dated: January 10, 2020	Forty Seven, Inc.
	By:	/s/ Mark A. McCamish
		Mark A. McCamish, M.D.
		President and Chief Executive Officer

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Forty Seven and the acquisition of Forty Seven by Gilead that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of the companies’ and members of their senior management team. Forward-looking statements include, without limitation, statements regarding the business combination and related matters, prospective performance and opportunities, post-closing operations and the outlook for the companies’ businesses, including, without limitation, the ability of Gilead to advance Forty Seven’s product pipeline, including magrolimab, FSI-174 and FSI-189; regulatory approval of magrolimab, FSI-174 and FSI-189 on a timely basis; the anticipated timing of clinical data; the possibility of unfavorable results from clinical trials; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; difficulties or unanticipated expenses in connection with integrating the companies; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Forty Seven’s stockholders will tender their stock in the Offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of the transaction on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; other business effects, including the effects of industry, economic or political conditions outside of the companies’ control; transaction costs; actual or contingent liabilities; and other risks and uncertainties detailed from time to time in the companies’ periodic reports filed with the SEC, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by Forty Seven and the Schedule TO and related tender offer documents to be filed by Gilead and Toro Merger Sub, Inc., a wholly owned subsidiary of Gilead. All forward-looking statements are based on information currently available to Gilead and Forty Seven, and Gilead and Forty Seven assume no obligation and disclaim any intent to update any such forward-looking statements.

Additional Information and Where to Find It

The Offer described in this Current Report on Form 8-K has not yet commenced. This Current Report on Form 8-K is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Forty Seven, nor is it a substitute for any tender offer materials that Gilead, its acquisition company or Forty Seven will file with the SEC. A solicitation and an offer to buy shares of Forty Seven will be made only pursuant to an offer to purchase and related materials that Gilead intends to file with the SEC. At the time the Offer is commenced, Gilead will file a Tender Offer Statement on Schedule TO with the SEC, and Forty Seven will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. FORTY SEVEN’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of Forty Seven at no expense to them. The Tender Offer Statement and the Solicitation/Recommendation Statement will be made available for free at the SEC’s web site at www.sec.gov. Additional copies may be obtained for free by contacting Gilead or Forty Seven. Free copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the Offer, which will be named in the Tender Offer Statement. Copies of the documents filed with the SEC by Forty Seven will be available free of charge under the “Investors” section of Forty Seven’s internet website at ir.fortyseveninc.com.

In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Gilead and Forty Seven file annual, quarterly and current reports, proxy statements and other information with the SEC. Gilead’s and Forty Seven’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.


Exhibit		Description

2.1*		Agreement and Plan of Merger, dated as of March 1, 2020, by and among Forty Seven, Inc., Gilead Sciences, Inc. and Toro Merger Sub, Inc.

99.1		Joint Press Release, dated March 2, 2020.

*	Schedules omitted pursuant to Item 601 of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 2, 2020


By:		/s/ Mark A. McCamish
		Mark A. McCamish, M.D.
		President and Chief Executive Officer

Filing Compare · Forty Seven, Inc.